Back to top

Image: Bigstock

Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in Session

Read MoreHide Full Article

Xeris Pharmaceuticals, Inc. (XERS - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.70–$3.52 in the past one-month time frame, witnessed a sharp increase yesterday.

The upmove came after the company's second quarter earnings trumped estimates.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Xeris Pharmaceuticals has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Another stock worth considering in the Medical - Drugs industry is Pacira BioSciences, Inc. (PCRX - Free Report) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.

The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Pacira BioSciences, Inc. (PCRX) - free report >>

Xeris Pharmaceuticals, Inc. (XERS) - free report >>